Biotech entity
All 2 tracked stories fall under one category: pharma. Of the tracked stories, 2 of 2 also mention Eli Lilly, the most common co-covered peer. The 20-day window averages about 0.7 stories each week. The 6.5 average consequence score is above the beat benchmark of 6.1 in the same window.
Last mentioned: Mar 23, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. Of the tracked stories, 2 of 2 also mention Eli Lilly, the most common co-covered peer. The 20-day window averages about 0.7 stories each week. The 6.5 average consequence score is above the beat benchmark of 6.1 in the same window. They are better corroborated than the beat average, carrying 3.5 original sources each against 3.4 for the same window. orforglipron appears in 2 tracked Biotech stories published from March 4, 2026 through March 23, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 289 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering orforglipron. Shared-story counts are live from our verified record — not editorial picks.
JPM Earnings
JPMorgan Chase reports Q1 results amid regulatory and legal headwinds.
FDA Decision Date
Expected regulatory ruling on orforglipron oral weight loss drug.
Zepbound Approval
FDA expands tirzepatide approval to include chronic weight management.
Mounjaro Launch
Tirzepatide enters the market for Type 2 Diabetes treatment.
Eli Lilly (LLY) is approaching a pivotal April 10 regulatory milestone for orforglipron, its experimental oral GLP-1 receptor agonist, as it seeks to expand its $11 billion weight-loss portfolio. While the broader market faces volatility from the banking sector's upcoming earnings on April 14, the biotech industry is laser-focused on the potential shift from injectable to oral metabolic therapies.
As market volatility persists in early 2026, Eli Lilly and Veeva Systems emerge as top growth picks driven by the obesity drug boom and AI integration. With Eli Lilly's tirzepatide securing its spot as the world's top-selling drug and new oral GLP-1s on the horizon, the pharmaceutical landscape is shifting toward tech-heavy, high-margin innovation.
orforglipron is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
